One of the demands raised during the protests was access to 'Elevidys', a one-time gene therapy treatment that has the ...
When her son reached three last year, a new name loomed over their lives — Duchenne Muscular Dystrophy (DMD), a ...
The EMA has called a temporary halt to a phase 2 trial of Sarepta's Roche-partnered Duchenne muscular dystrophy (DMD) gene ...
The European Medicines Agency has temporarily suspended enrollment and dosing in a Phase II trial of Sarepta Therapeutics' ...
President Trump yesterday announced a baseline tariff of 10% on all imported products and higher rates on certain countries ...
Discover growth opportunities with Edgewise Therapeutics, Inc. in the hypertrophic cardiomyopathy market. Click for my EWTX ...
In response to a request from the European Medicines Agency (EMA) following the death of a 16-year-old patient in the U.S., ...
Barry Byrne, MD, PhD, Powell Gene Therapy Center at the University of Florida, discusses gene therapy considerations for pediatric patients and how newborn screening can influence outcomes for ...
Investor's Business Daily on MSN2h
Sarepta Plunges After EMA Puts Gene Therapy Studies On Hold Following Teen's DeathSarepta stock plunged Thursday after European officials put all studies of the company's gene therapy, Elevidys, on hold.
Edgewise Therapeutics plans to sell nearly 10 million shares of its common stock at $20.13, raising $200 million.
Florida leaders can enact a new law, the Right to Try for Individualized Treatments, that allows Floridians with rare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback